Evidence map›Paper›PMID 17050593›Full record

Trial reportJournal of virology2007

Comparison of the influenza virus-specific effector and memory B-cell responses to immunization of children and adults with live attenuated or inactivated influenza virus vaccines.

Sanae Sasaki, Maria C Jaimes, Tyson H Holmes, Cornelia L Dekker, Kutubuddin Mahmood, George W Kemble, Ann M Arvin, Harry B Greenberg

2 registry-linked trialsOpen access · bronzeAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Journal of virology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 101 papers.

0numbers the graph read from it
0cells of the map it votes in
101citing papers in PubMed
5.7field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01097941 phase4withdrawnnot on this mapstarted 2010, after this paper: background citation

Evaluation of the Effect of Age and Prior Immunity on the Response to Live or Inactivated A/California/07/09 H1N1 Influenza Vaccines in Children

TypeinterventionalSponsorUniversity of RochesterRan2010 to 2010Enrolled0Conditions2009 H1N1 InfluenzaArmsLive Attenuated H1N1 Influenza Vaccine, Influenza A (H1N1) 2009 Monovalent Vaccine, Influenza A (H1N1) 2009 Monovalent Vaccine/ Influenza A (H1N1) Monovalent Vaccine Live
NCT01246999 phase4completednot on this mapstarted 2010, after this paper: background citation

Evaluation of the Effect of Age and Prior Immunity on the Response to Live or Inactivated Seasonal (A/California/7/2009-like, A/Perth/16/2009-like, and B/Brisbane/60/2008-like (B/Victoria Lineage) Influenza Vaccines in Children

TypeinterventionalSponsorUniversity of RochesterRan2010 to 2013Enrolled34ConditionsInfluenzaArmsLive attenuated Influenza vaccine, Trivalent Influenza Vaccine, TIV followed by LAIV, LAIV followed by TIV
3 · Its place in the literature

Who cites it

101 citing papers in PubMed, 189 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels.Proceedings of the National Academy of Sciences of the United States of America · 2009
    Trial
  7. Trial
  8. Human Organoids as a Novel Tool for Vaccine Study.Advanced healthcare materials · 2026
    Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Factors influencing the immunogenicity of influenza vaccines.Human vaccines & immunotherapeutics · 2021
    Review

41 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Sanae SasakiDepartment of Medicine, Stanford University School of Medicine, CA, USA.
Maria C Jaimes
Tyson H Holmes
Cornelia L Dekker
Kutubuddin Mahmood
George W Kemble
Ann M Arvin
Harry B Greenberg
Stanford University · USVA Palo Alto Health Care System · US

Funding

Using a tonsil organoid system to probe conditions for the induction of protective antibody and T cell responses to influenza.U19AI057229 · NIAID · STANFORD UNIVERSITY · PI Mark Morris Davis · 2003 to 2026
$88.5M
XOLAIR IN SUBJECTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS WITH FOOD ALLERGYM01RR000070 · NCRR · STANFORD UNIVERSITY · PI RASGON, NATALIE L · 1985 to 2008
$32.4M
Proteomics/GenomicsP30DK056339 · NIDDK · STANFORD UNIVERSITY · PI GREENBERG, HARRY BERNARD · 2001 to 2010
$10.4M
NCRR NIH HHS 5M01RR00070NCRR NIH HHS M01 RR000070NIAID NIH HHS AI057229NIAID NIH HHS U19 AI057229NIDDK NIH HHS DK56339NIDDK NIH HHS P30 DK056339
6 · The paper itself

Abstract

Cellular immune responses to influenza virus infection and influenza virus vaccination have not been rigorously characterized. We quantified the effector and memory B-cell responses in children and adults after administration of either live attenuated (LAIV) or inactivated (TIV) influenza virus vaccines and compared these to antibody responses. Peripheral blood mononuclear cells were collected at days 0, 7 to 12, and 27 to 42 after immunization of younger children (6 months to 4 years old), older children (5 to 9 years old), and adults. Influenza virus-specific effector immunoglobulin A (IgA) and IgG circulating antibody-secreting cells (ASC) and stimulated memory B cells were detected using an enzyme-linked immunospot assay. Circulating influenza virus-specific IgG and IgA ASC were detected 7 to 12 days after TIV and after LAIV immunization. Seventy-nine percent or more of adults and older children had demonstrable IgG ASC responses, while IgA ASC responses were detected in 29 to 53% of the subjects. The IgG ASC response rate to LAIV immunization in adults was significantly higher than the response rate measured by standard serum antibody assays (26.3% and 15.8% by neutralization and hemagglutination inhibition assays, respectively). IgG ASC and serum antibody responses were relatively low in the younger children compared to older children and adults. TIV, but not LAIV, significantly increased the percentage of circulating influenza virus-specific memory B cells detected at 27 to 42 days after immunization in children and adults. In conclusion, although both influenza vaccines are effective, we found significant differences in the B-cell and antibody responses elicited after LAIV or TIV immunization in adults and older children and between young children and older age groups.

Indexed as

Immunologic MemoryAdultAge FactorsAntibodies, ViralAntibody-Producing CellsB-LymphocytesChildChild, PreschoolHumansImmunoglobulin AImmunoglobulin GInfantInfluenza VaccinesVaccines, AttenuatedVaccines, InactivatedAntibodies, ViralImmunoglobulin AImmunoglobulin GInfluenza VaccinesVaccines, AttenuatedVaccines, Inactivated

Identifiers

PMID17050593
PMCPMC1797237
OpenAlexW1990429464

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.